Bioceltix (BCX) Q3 2024 earnings summary

Executive summary

• Advanced clinical development for three stem cell-based veterinary drugs: BCX-CM-J (osteoarthritis in dogs), BCX-CM-AD (atopic dermatitis in dogs), and BCX-EM (joint inflammation in horses), with positive clinical milestones reached for each.

• EMA accepted the registration dossier for BCX-CM-J, confirming no safety or efficacy concerns; final questions from EMA received, with optimism for approval.

• Clinical trials for BCX-EM showed statistically significant efficacy; dossier submission to EMA planned for early 2025.

• BCX-CM-AD clinical trial recruitment completed; interim analysis allowed for a reduced patient number due to strong efficacy signals.

• Construction of a new large-scale GMP manufacturing facility is underway, with space secured and building to start in Q2 2025.

Financial highlights

• No revenue from product sales; operations funded by equity and grants.

• Net loss for Q3 2024: PLN -3.45 million; YTD net loss: PLN -11.88 million, higher than the same period last year.

• Net cash from financing activities YTD: PLN 42.27 million, mainly from a new share issue.

• Cash and equivalents at period end: PLN 38.2 million, up from PLN 9.3 million at 2023 year-end.

• Equity increased to PLN 41.43 million, with a book value per share of PLN 8.41.

Outlook and guidance

• Sufficient funding secured for at least 12 months of operations following a successful share issue.

• Focus remains on completing clinical trials, regulatory submissions, and scaling up manufacturing.

• No financial forecasts published.